0DL.F BIOSYNEX INH. EO-10
- Market cap
- EUR 14.8M
- P/E
- -
- P/B
- 0.41x
- ROE
- -166.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0DL.F undervalued?
Graham numberThe Graham number of BIOSYNEX INH. EO-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOSYNEX INH. EO-10 fundamental analysis
No fundamental analysis for BIOSYNEX INH. EO-10 yet.
BIOSYNEX INH. EO-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOSYNEX INH. EO-10
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy …
Full company profileBIOSYNEX INH. EO-10 financial statements
BIOSYNEX INH. EO-10 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 383M | 197M | 93.0M | 101M | 95.2M |
| Gross Profit | 206M | 102M | 49.1M | 57.4M | 52.4M |
| Operating Income | 141M | 35.1M | -37.4M | -36.3M | -63.3M |
| EBITDA | - | 51.7M | -11.5M | -19.0K | 1.20M |
| Net Income | 104M | 15.7M | -36.9M | -43.3M | -58.2M |
| EPS | 8.32 | 1.26 | -2.92 | -3.43 | -3.16 |
| Balance Sheet | |||||
| Total Assets | 269M | 260M | 242M | 195M | 136M |
| Total Liabilities | 101M | 93.4M | 117M | 114M | 101M |
| Shareholders' Equity | 168M | 163M | 124M | 80.6M | 35.0M |
| Cash & Short-term Investments | 132M | 87.2M | 20.2M | 4.69M | 8.46M |
| Cash Flow | |||||
| Operating Cash Flow | 110M | 4.95M | -9.65M | -10.1M | -5.89M |
| Capital Expenditure | 19.0M | 37.8M | 39.5M | 4.84M | 2.69M |
| Free Cash Flow | 90.8M | -32.8M | -49.2M | -15.0M | -8.57M |
| Ratios | |||||
| ROE | 62.0% | 9.6% | -29.7% | -53.8% | -166.6% |
| ROA | 38.7% | 6.0% | -15.3% | -22.3% | -42.7% |
| Net Profit Margin | 27.2% | 8.0% | -39.7% | -42.8% | -61.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOSYNEX INH. EO-10 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 16, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 20.4M | 1.65 | 130.6% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BIOSYNEX INH. EO-10
- Insiders 57.61%
- Institutions 0.00%
- Public & others 42.40%
- Shares outstanding 18.4M
- Free float 7.63M
BIOSYNEX INH. EO-10 company profile
- Company name
- BIOSYNEX INH. EO-10
- Ticker
- 0DL.F
- ISIN
- FR0011005933
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 397
- Fiscal year end
- December
- Address
- 22 Boulevard SEbastien Brant, Illkirch-Graffenstaden, France, 67400
- Phone
- 33 3 88 78 78 87
- Website
- biosynex.com
About BIOSYNEX INH. EO-10
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizing, and sensitive skin spray. The company was incorporated in 2005 and is based in Illkirch-Graffenstaden, France.
BIOSYNEX INH. EO-10 management
2- Mr. Larry AbensurChairman & CEO
- Dr. Thierry PaperDeputy CEO & Director